We are building the tools to radically accelerate therapeutic innovation – streamlining development, verification, and regulatory approval for next-generation treatments.

The Problem

The pathway for new therapeutics is long and treacherous. It takes more than a decade and hundreds of millions of dollars for a therapy to reach the market. Despite this, 90% of drugs that make it as far as clinical trials still fail. Each failure represents not just wasted resources, but a story of lost time and missed opportunity for patients.

The Opportunity

A new generation of therapeutic modalities is reshaping medicine. Carrier technologies, like mRNA-encapsulating lipid nanoparticles, are rewriting the rules, enabling complex payloads to be delivered directly to target cells with minimal toxic side effects.

But the clinical pathway is still broken. Using preclinical data to predict performance in the complex environment of the human body is unreliable. This leaves carrier design dependent on trial and error – wasting time, capital, and opportunity.

The reason is clear: we’re still using the development playbook built for small molecule drugs. Carriers are fundamentally different, and demand a new way of thinking. By embracing their unique biological and physical behaviour, we can unlock their full potential and bring therapies to patients faster.

Our Vision

At Pneumatica Bio, we’re writing a new playbook. We believe that the future is interdisciplinary. By uniting fields and perspectives, we move faster, smarter, and together.

We employ sophisticated and automated biological assays in concert with cutting-edge computational, mathematical and statistical techniques to predict the biodistribution of carrier-based therapeutics. Our efficient and high-throughput technical platform mitigates financial risks in clinical trials and streamlines drug development pipelines.

We will realise the potential of these revolutionary therapies, and turn preclinical promise into real impact for patients.